for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aspen Technology, Inc.

AZPN.OQ

Latest Trade

118.43USD

Change

-0.15(-0.13%)

Volume

2,808

Today's Range

117.77

 - 

118.81

52 Week Range

75.10

 - 

141.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
118.58
Open
118.47
Volume
2,808
3M AVG Volume
8.67
Today's High
118.81
Today's Low
117.77
52 Week High
141.82
52 Week Low
75.10
Shares Out (MIL)
68.21
Market Cap (MIL)
8,066.28
Forward P/E
31.28
Dividend (Yield %)
--

Next Event

Aspen Technology Inc Annual Shareholders Meeting

Latest Developments

More

Aspen Technology Inc - Determined Reports For Qtrs Ended Sept. 30, 2018, Dec. 31, 2018 And Mar. 31, 2019, Should Not Be Relied Upon

Aspen Technology Inc Says Identified Errors In Transition Adjustment Related To Revenue From Contracts With Customers Recorded As Of June 30, 2016

Aspen Technology Announces Financial Results For The Fourth Quarter And Fiscal Year 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aspen Technology, Inc.

Aspen Technology, Inc. is a global provider of process optimization software solutions designed to manage and optimize plant and process design, operational performance, and supply chain planning. The Company's aspenONE software and related services have been developed specifically for companies in the process industries, including the energy, chemicals, and engineering and construction industries. It operates through two segments, including subscription and software, which provides licensing of process optimization software solutions and associated support services, and services, which includes professional services and training. It has developed applications to design and optimize processes across the business areas, including engineering, manufacturing and supply chain. Its products include Aspen HYSYS, Aspen Economic Evaluation, Aspen Info Plus.21, Aspen PIMS Advanced Optimization, Aspen Collaborative Demand Manager and Aspen Supply Planner.

Industry

Software & Programming

Contact Info

20 Crosby Dr

+1.781.2214302

http://www.aspentech.com

Executive Leadership

Robert M. Whelan

Independent Chairman of the Board

Antonio J. Pietri

President, Chief Executive Officer, Director

Karl E. Johnsen

Chief Financial Officer, Senior Vice President

Gary M. Weiss

Chief Operating Officer

Frederic G. Hammond

Senior Vice President, General Counsel, Secretary

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.5K

2018

0.5K

2019

0.6K

2020(E)

0.6K
EPS (USD)

2017

2.300

2018

2.310

2019

4.090

2020(E)

3.781
Price To Earnings (TTM)
30.58
Price To Sales (TTM)
13.05
Price To Book (MRQ)
20.54
Price To Cash Flow (TTM)
28.90
Total Debt To Equity (MRQ)
81.37
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
45.87
Return on Equity (TTM)
28.92

Latest News

Latest News

BRIEF-Aspen Technology Q3 Non-GAAP Earnings Per Share $0.58

* ASPEN TECHNOLOGY ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2018

BRIEF-Emerson And Aspentech To Form Alliance To Deliver Digital Technologies

* EMERSON SAYS CO AND ASPENTECH FORM ALLIANCE TO DELIVER DIGITAL TECHNOLOGIES

BRIEF-Aspentech Acquires Apex Optimisation, Inventors Of Generic Dynamic Optimisation Technology (Gdot)

* ASPENTECH ACQUIRES APEX OPTIMISATION, INVENTORS OF GENERIC DYNAMIC OPTIMISATION TECHNOLOGY (GDOT)

BRIEF-Aspen Technology Q2 Earnings Per Share $0.52

* ASPEN TECHNOLOGY ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018

BRIEF-Mylan And Aspen Announce Launch Of Generic Busulfex Injection

* MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION

BRIEF-Aspen Technology Q1 non-GAAP earnings per share $0.53

* Aspen technology announces financial results for the first quarter of fiscal 2018

UK anti-trust regulator investigates South Africa's Aspen Pharmacare

Britain's competition regulator has launched an investigation into Africa's biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

South Africa watchdog drops over-charging probe into Aspen, Equity

South Africa's competition watchdog has dropped an investigation into Aspen Pharmacare and Equity Pharmaceutical, saying a case against them for over-charging for cancer medicines "cannot be sustained."

S.Africa watchdog drops over-charging probe into Aspen, Equity

South Africa's competition watchdog has dropped an investigation into Aspen Pharmacare and Equity Pharmaceutical, saying a case against them for over-charging for cancer medicines "cannot be sustained."

CORRECTED-South Africa's Aspen Pharmacare flags jump in full-year profit

South African drugmaker Aspen Pharmacare said on Wednesday that it expects full-year profit to climb by as much as 48 percent from last year when it was hit by a writedown on its Venezuelan business.

BRIEF-Aspen Technology Q4 non-GAAP earnings per share $0.79

* Aspen Technology announces financial results for the fourth quarter and fiscal year 2017

Aspen under EU antitrust spotlight over excessive cancer drug prices

EU antitrust regulators will investigate whether Aspen Pharmacare is charging excessive prices for five key cancer drugs in a move which could lead to a hefty fine for Africa's largest generic drugmaker.

BRIEF-Aspen Technology announces Q3 earnings per share $0.47

* Aspen Technology announces financial results for the third quarter of fiscal 2017

BRIEF-Aspen technology reports Q2 adj EPS $0.52

* Aspen technology announces financial results for the second quarter of fiscal 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up